ImaginAb Announces Licensing Deal with AstraZeneca for CD8 ImmunoPET Technology

Los Angeles, CA, USA, March 30, 2020 – ImaginAb Inc., a leading clinical stage immuno-oncology imaging company, today announced it has signed a multi-year non-exclusive license agreement with AstraZeneca.

Under the terms of the agreement, ImaginAb’s CD8 ImmunoPET technology will be used in AstraZeneca’s clinical trials in North America and Europe to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...